SS Innovations Achieves Significant Milestones in 2023

Company’s award winning SSi Mantra surgical robotic system has completed over 550 surgeries and is clinically validated to perform more than 40 different types of surgical procedures

Company Builds Strong Foundation for Future Growth

FORT LAUDERDALE, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today provided shareholders and the investment community with a review of the significant milestones the Company achieved in 2023.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, and a pioneer in robotic cardiothoracic surgery, stated, “SS Innovations built a strong foundation in 2023 and has laid the groundwork to achieve significant milestones in the years ahead. Since we completed our merger transaction with publicly held AVRA Medical Robotics and began trading in the U.S. on the OTC Market in April 2023 under our new name, SS Innovations International, Inc. and our new trading symbol, “SSII,” our SSi Mantra robotic surgical system has been clinically validated for additional surgical procedures across multiple specialties and is now being utilized in more than 40 different types including thoracic, cardiac, pediatric, gynecologic, urologic, general surgery, and head and neck surgeries.

“In the past nine months we have achieved many milestones that included placing our first system in a Central Government Institution in India and receiving regulatory approval from the Guatemala Ministry of Health, our second approval in addition to that from CDSCO, the Indian Regulatory Body. We also recently entered into a co-development partnership agreement with Johns Hopkins University, a memorandum of understanding with Surgical Lab, Ltd., for a strategic distribution partnership for placement across 27 countries in Africa and an exclusive partnership with MIMA, a prominent distribution company based in Tbilisi, Georgia, for distribution of the SSi Mantra throughout CIS countries in Central Asia such as the Republic of Georgia, Kazakhstan, Azerbaijan, Turkmenistan and Moldova. With growing placements of our award-winning robotic surgical system, we are nearing achievement of our next surgical milestone of 1,000 cases after surpassing 550 surgical procedures just several weeks ago.”